Paladin Wealth LLC Acquires 2,179 Shares of DexCom, Inc. (NASDAQ:DXCM)

Paladin Wealth LLC grew its holdings in DexCom, Inc. (NASDAQ:DXCM) by 34.4% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 8,514 shares of the medical device company’s stock after buying an additional 2,179 shares during the quarter. Paladin Wealth LLC’s holdings in DexCom were worth $662,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Dynamic Advisor Solutions LLC boosted its holdings in DexCom by 14.6% during the third quarter. Dynamic Advisor Solutions LLC now owns 3,077 shares of the medical device company’s stock valued at $206,000 after purchasing an additional 391 shares in the last quarter. Livforsakringsbolaget Skandia Omsesidigt boosted its stake in DexCom by 290.7% in the 3rd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 3,387 shares of the medical device company’s stock valued at $227,000 after buying an additional 2,520 shares in the last quarter. Valeo Financial Advisors LLC grew its position in DexCom by 31.8% in the third quarter. Valeo Financial Advisors LLC now owns 10,041 shares of the medical device company’s stock valued at $673,000 after acquiring an additional 2,424 shares during the period. Gateway Investment Advisers LLC raised its stake in DexCom by 9.1% during the third quarter. Gateway Investment Advisers LLC now owns 8,832 shares of the medical device company’s stock worth $592,000 after acquiring an additional 740 shares in the last quarter. Finally, Exchange Traded Concepts LLC lifted its holdings in shares of DexCom by 39.5% during the third quarter. Exchange Traded Concepts LLC now owns 12,276 shares of the medical device company’s stock valued at $823,000 after acquiring an additional 3,474 shares during the period. 97.75% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. Raymond James dropped their target price on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a research report on Friday, October 25th. Wells Fargo & Company lifted their target price on shares of DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. StockNews.com lowered DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Oppenheimer dropped their price target on DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Finally, Leerink Partners decreased their target price on DexCom from $90.00 to $87.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. Four research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, DexCom presently has a consensus rating of “Moderate Buy” and an average target price of $98.41.

Insider Activity

In other DexCom news, EVP Jereme M. Sylvain sold 2,090 shares of the stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $181,641.90. Following the transaction, the executive vice president now owns 83,526 shares of the company’s stock, valued at approximately $7,259,244.66. This represents a 2.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Kevin R. Sayer sold 33,359 shares of the firm’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $2,899,230.69. Following the transaction, the chief executive officer now owns 319,037 shares in the company, valued at approximately $27,727,505.67. This trade represents a 9.47 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 42,342 shares of company stock valued at $3,628,069 in the last 90 days. 0.30% of the stock is owned by company insiders.

DexCom Price Performance

Shares of DXCM stock opened at $88.27 on Tuesday. The firm’s 50 day moving average price is $81.76 and its two-hundred day moving average price is $75.11. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00. The stock has a market cap of $34.48 billion, a PE ratio of 52.86, a PEG ratio of 2.26 and a beta of 1.14.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.